Vitrolife Update: Good efforts in a challenging period - Redeye

Vitrolife faces a tough start in 2025, and we expect this to continue during H1 2025. In short, Vitrolife is stepping up its investments in commercial capacity and sales during a period of softer organic growth. In Q1, the softer areas are the APAC regions and technologies, apart from pressure in OPEX and operating cash flow.

Länk till analysen i sin helhet: https://www.redeye.se/research/1098728/vitrolife-update-good-efforts-in-a-challenging-period?utm_source=finwire&utm_medium=RSS